NCT00130962View on ClinicalTrials.gov

ALGRX 4975 in the Treatment of Patients With Morton's Neuroma

PHASE2CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

September 30, 2004

Study Completion Date

February 28, 2006

Conditions
Neuroma
Interventions
DRUG

ALGRX 4975

Trial Locations (2)

21117

Crossroads Research, Inc., Owings Mills

84124

Jean Brown Research, Salt Lake City

Sponsors
All Listed Sponsors
lead

AlgoRx Pharmaceuticals

INDUSTRY

NCT00130962 - ALGRX 4975 in the Treatment of Patients With Morton's Neuroma | Biotech Hunter | Biotech Hunter